FATE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FATE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-10-08), Fate Therapeutics's current share price is $3.065. Fate Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was $3.84. Fate Therapeutics's Cyclically Adjusted PB Ratio for today is 0.80.
The historical rank and industry rank for Fate Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Fate Therapeutics's highest Cyclically Adjusted PB Ratio was 26.48. The lowest was 0.44. And the median was 1.72.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Fate Therapeutics's adjusted book value per share data for the three months ended in Jun. 2024 was $3.487. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.84 for the trailing ten years ended in Jun. 2024.
The historical data trend for Fate Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | - | - | 26.43 | 3.14 | 1.01 |
Fate Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 1.38 | 0.57 | 1.01 | 1.94 | 0.85 |
For the Biotechnology subindustry, Fate Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Fate Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 3.065 | / | 3.84 | |
= | 0.80 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:
For example, Fate Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:
Adj_Book | = | Book Value per Share | / | CPI of Jun. 2024 (Change) | * | Current CPI (Jun. 2024) |
= | 3.487 | / | 132.5538 | * | 132.5538 | |
= | 3.487 |
Current CPI (Jun. 2024) = 132.5538.
Fate Therapeutics Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201409 | 1.633 | 100.428 | 2.155 |
201412 | 1.378 | 99.070 | 1.844 |
201503 | 1.030 | 99.621 | 1.370 |
201506 | 1.785 | 100.684 | 2.350 |
201509 | 1.567 | 100.392 | 2.069 |
201512 | 1.325 | 99.792 | 1.760 |
201603 | 1.065 | 100.470 | 1.405 |
201606 | 0.801 | 101.688 | 1.044 |
201609 | 0.743 | 101.861 | 0.967 |
201612 | 1.768 | 101.863 | 2.301 |
201703 | 1.542 | 102.862 | 1.987 |
201706 | 1.333 | 103.349 | 1.710 |
201709 | 1.103 | 104.136 | 1.404 |
201712 | 1.466 | 104.011 | 1.868 |
201803 | 1.230 | 105.290 | 1.549 |
201806 | 0.971 | 106.317 | 1.211 |
201809 | 2.696 | 106.507 | 3.355 |
201812 | 2.480 | 105.998 | 3.101 |
201903 | 2.240 | 107.251 | 2.768 |
201906 | 1.953 | 108.070 | 2.395 |
201909 | 3.554 | 108.329 | 4.349 |
201912 | 3.232 | 108.420 | 3.951 |
202003 | 2.885 | 108.902 | 3.512 |
202006 | 5.462 | 108.767 | 6.656 |
202009 | 4.877 | 109.815 | 5.887 |
202012 | 4.382 | 109.897 | 5.285 |
202103 | 8.415 | 111.754 | 9.981 |
202106 | 7.978 | 114.631 | 9.225 |
202109 | 7.659 | 115.734 | 8.772 |
202112 | 7.091 | 117.630 | 7.991 |
202203 | 6.561 | 121.301 | 7.170 |
202206 | 5.993 | 125.017 | 6.354 |
202209 | 5.334 | 125.227 | 5.646 |
202212 | 4.974 | 125.222 | 5.265 |
202303 | 4.863 | 127.348 | 5.062 |
202306 | 4.443 | 128.729 | 4.575 |
202309 | 4.086 | 129.860 | 4.171 |
202312 | 3.735 | 129.419 | 3.825 |
202403 | 3.744 | 131.776 | 3.766 |
202406 | 3.487 | 132.554 | 3.487 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Fate Therapeutics (NAS:FATE) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Fate Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Yuan Xu | director | C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Dulac Edward J Iii | officer: Chief Financial Officer | FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121 |
J Scott Wolchko | director, officer: President and CEO | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Bahram Valamehr | officer: Chief Development Officer | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121 |
Cindy Tahl | officer: See Remarks | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121 |
Redmile Group, Llc | director, 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Brian T. Powl | officer: Chief Commercial Officer | C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131 |
Yu-waye Chu | officer: See Remarks | FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121 |
John Mendlein | director | |
Mark Plavsic | officer: Chief Technical Officer | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121 |
Shefali Agarwal | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Karin Jooss | director | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Timothy P Coughlin | director | 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075 |
Robert Hershberg | director | 3005 FIRST AVENUE, SEATTLE WA 98121 |
Robert S Epstein | director |
From GuruFocus
By PRNewswire • 06-13-2024
By Marketwired • 05-03-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 05-06-2024
By Marketwired • 08-13-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 07-31-2024
By GuruFocus Research • 05-10-2024
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.